CBC Health Clinic, Munich, Germany. Umbilical cord blood stem cell treatment in Germany
In Europe, clinical and experimental teams are utilizing some of the methods and technologies being studied in U.S. clinical trials and combining them with CBC Health Clinic Munich’s experience with umbilical cord blood infusion treatments to provide therapeutic solutions for ischemic stroke survivors from around the world. This ischemic stroke treatment is available in our specially designed day-clinic in Munich, Germany.
In the clinic, the treatment of umbilical cord stem cells is available not only for stroke, but also for other diseases.
Combining Innovation with 20 Years of Cord Blood Banking Experience
The research-based treatments use cord blood components provided by CBC Health Clinic Munich’s parent company, Cord Blood Center Group, which is known for providing therapeutic components with above-average quantities of nucleated cells. We have over 20 years of experience in cord blood banking and offer treatments utilizing allogeneic cord blood.
Cord Blood Based Ischemic Stroke Recovery Treatment
Cord blood infusion is not intended to be a replacement for standard therapy in the management of stroke; however, it is an additional therapeutic approach that may gain additional improvement of cognitive and motor functions.
Intravenous infusion of umbilical blood cells is a therapeutic procedure used in patients recovering from stroke. Umbilical cord blood is collected from placenta via the umbilical cord vein. To achieve an optimum therapeutic effect, a dose of 50 million cells per kg is required, and each infusion includes cord blood collected from 4 to 8 donors.
The entire course of infusions is scheduled over two to three days, and after each infusion, the patient is monitored for several hours for any potential adverse reactions.
In the majority of patients, cord blood infusions have resulted in improvement of cognitive and motor functions. These functional gains become noticeable within the first few weeks after the infusion and continue for the next 3 to 6 months. Adverse reactions to cord blood cell infusions are rare and generally mild.
The Treatment Effect
Intravenous cord blood cell infusions enhance the regenerative activity of brain cells in stroke patients. Clinical studies suggest that cord blood therapy is more effective when administrated soon after stroke occurs.
Patients begin to notice improvements within a few weeks after the infusion. The cord blood cells are eliminated from the patient’s body within 6 to 8 weeks; however, patients experience functional gains over the next 3 to 6 months, with sustained functional improvement. Achieved improvement is permanent; patients do not experience worsening of the achieved improvement. Another study suggests that repeated cord blood infusions might lead to further functional improvements
Clinical studies have shown that the most important factor influencing the therapeutic effect of cord blood infusion is cell dosage. In a recent clinical trial at Duke University on pediatric cerebral palsy patients (mostly induced by stroke), only patients who received more than 25 million cells per kg showed significant therapeutic effect (Kurtzberg et al; Blood 2015). In each of our cord blood infusions, the patient receives a standard of more than 50 million cells per kg.
- Transportation services
- Personal escort available
- Flight arrangements
- Electronic medical records
- Interpreters available on demand
- Accommodation arrangements
- Doctors have liability insurance yes